AWARD NUMBER DAMD17-94-J-4369

TITLE: Programmed Cell Death Pathways in Tumor Initiation & Progresssion

PRINCIPAL INVESTIGATOR: David M. Hockenbery, M.D.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Center Seattle, Washington 98104

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander

U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;

distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

### REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services. Directorate for information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503. 1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED October 1997 ANNUAL 16 Sept 96 - 15 Sept 97 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Programmed Cell Death Pathways in Tumor Initiation and Progression DAMD17-94-J-4369 6. AUTHOR(S) David M. Hockenbery, M.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESSIES) 8. PERFORMING ORGANIZATION REPORT NUMBER Fred Hutchinson Cancer Research Center Seattle, Washington 98104 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING/MONITORING AGENCY REPORT NUMBER U.S. Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION/AVAILABILITY STATEMENT 19980722 062 Approved for public release; distribution unlimited 13. ABSTRACT (Maximum 200 words) The effects of cellular apoptotic regulators on tumor initiation and progression are difficult to predict, as oncogenes may have either anti-apoptotic (bcl-2) and pro-apoptotic (c-myc) effects. Anti-apoptotic genes may promote tumor growth by rescuing cells susceptible to apoptosis, due to DNA damage, for example. Pro-apoptotic genes, on the other hand, might increase DNA damage as a substrate for genetic instability. We tested the ability of transgenic bcl-2 to interact with DMBA in the formation of murine mammary tumors. A modest increase in tumor incidence at early time points (7-8 weeks post exposure) was observed in DMBA-treated transgenic vs control female mice. We have examined mammary tumors from transgenic mice for apoptosis using the in situ TUNEL assay. Unexpectedly, apoptotic cells were present at relatively high levels, compared to normal breast tissue (20.5 +/- 12.7/hpf vs 14.2 +/- 4.8/hpf). Apoptosis is often associated with increased oxidative stress, a potential cause of DNA damage. We have examined Rat-1 cells undergoing c-myc-regulated cell death for early changes in mitochondrial structure and function. Induction of apoptosis led to initial mitochondrial proliferation followed by collapse of mitochondrial transmembrane potential. Increased numbers of mitochondria with a disorganized cristae and ultracondensed morphology were observed in myc-induced apoptosis. Constitutive c-myc expression has been demonstrated to lead to genetic instability. An association between mitochondrial dysfunction, ROS, and genetic instability may explain the apparent retention of apoptotic programs in experimental and human tumors. 14. SUBJECT TERMS 15. NUMBER OF PAGES apoptosis, bcl-2, mitochondria, oxidative stress 16 16. PRICE CODE **Breast Cancer** SECURITY CLASSIFICATION OF REPORT

18. SECURITY CLASSIFICATION

Unclassified

OF THIS PAGE

Unclassified

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) rescribed by ANY 318, 239-18

Unlimited

20. LIMITATION OF ABSTRACT

SECURITY CLASSIFICATION

OF ABSTRACT

Unclassified

#### FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army. Where copyrighted material is quoted, permission has been obtained to use such material. Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material. Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations. In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals, " prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985). NR For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46. In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health. In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules. In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

## **Table of Contents**

Introduction	.5
Body	.8
Conclusions	.14
References.	15

### Introduction

The bcl-2 gene is one of the best studied regulators of apoptosis, capable of inhibiting apoptotic cell deaths in a wide variety of experimental models (Hockenbery 1995). Several lines of evidence point to the importance of programmed cell death pathways as brakes against tumor development. The bcl-2 gene was first identified as an oncogene in follicular lymphomas bearing the t(14;18) chromosomal translocation. High bcl-2 expression in acute myelocytic leukemia correlates with poor chemotherapy responses and shortened survival (Campos and others 1993). Many studies implicate p53 function in apoptosis following gamma irradiation and exposure to certain chemotherapy drugs. Suppression of apoptosis during tumor growth is tightly linked to inhibition of p53 function and tumor progression in SV40 T antigen-induced choroid plexus tumors in transgenic mice, suggesting a wider role for p53 in apoptotic control (Symonds and others 1994).

Apoptotic mechanisms appear to be closely intertwined with other cellular processes, including cell division and differentiation (Rubin and others 1993), (Howard and others 1993). In support of this cross talk between pathways, overexpression of Bcl-2 has been shown to inhibit cell growth, promote G1-S cell cycle transition, or promote cellular differentiation in separate models (Pietenpol and others 1994), (Miyazaki and others 1995), (Linette and others 1994). Survival mediated by Bcl-2 in factor-deprived FDCPmix cells occurs with complete progression to differentiated

myeloid or erythroid phenotypes, while Bcl-xL maintains comparable survival of multipotent precursors. (Haughn and Hockenbery, unpublished data). The net effect of Bcl-2 overexpression in tumor cells is difficult to predict, in view of these multiple, sometimes opposing, effects. Although many tumors express high levels of Bcl-2, in breast cancers and an older age population with non-small cell lung cancers, Bcl-2 expression is correlated with a favorable prognosis (Joensuu and others 1994), (Leek and others 1994), (Bhargava and others 1994), (Pezzella and others 1993).

Paradoxically, several known oncogenes (c-fos, c-myc) are pro-apoptotic. Intermediate steps in transformation may be associated with lowered apoptotic thresholds (Preston and others, 1994). One possible explanation for these observations is that "apoptosis" contributes to full tumorigenicity in some way. While the phenotype of apoptotic death includes internucleosomal cleavage of DNA, whether sublethal activation of apoptotic pathways can occur is unknown. Infrequent double-stranded breaks may occur in this setting, which may increase the frequency of chromosomal rearrangements and amplifications, one form of genetic instability associated with tumors. The observation that Bcl-2 may inhibit apoptosis by increasing cellular resistance to oxidative stress is consistent with this hypothesis, as oxidative stress can be mutagenic and activate apoptotic cell death at different dose levels.

Based on experiments conducted in different systems, the anti-apoptotic effect of Bcl-2 could increase tumorigenesis, by sustaining cells that would be vulnerable to apoptosis at several steps in the tumorigenic process, or Bcl-2 could have a tumor suppressor effect, by inhibiting cell growth, promoting differentiation, or possibly by

counteracting a mechanism involved in genetic instability. While transgenic mice that express Bcl-2 in both B and T lymphocyte lineages are predisposed to cancer, the overall incidence of cancer is low and delayed when compared to other oncogenes. Other lineages that have been targeted for Bcl-2 overexpression in transgenic mice, including breast, intestine and myeloid, have not been noted to have an increased incidence of tumors (Lagasse and Weissman 1993), (Hockenbery, unpublished observations). Our goal is to determine the effect of bcl-2 overexpression in several tumor models and develop an understanding of how apoptosis interacts with the process of carcinogenesis, using breast cancer as our focus.

### **Body**

### Task 1 - Analysis of genetic instability in cell lines.

Cells triggered to undergo apoptosis have been found to have increased generation of reactive oxygen species. This change in redox state may be important in activation of caspase proteases, the executioners of apoptosis, as well as contribute to single-stranded DNA breaks observed in apoptosis (Nobel and others, 1997; Tschopp). The source of endogenous oxidative stress in apoptosis has been determined to be mitochondria, and the mechanisms of mitochondrial dysfunction in apoptosis remains an important problem in apoptosis research. Bcl-2 and other anti-apoptotic proteins are localized to mitochondrial membranes and prevent ROS generation as well as altered mitochondrial function during apoptosis. Bax, a pro-apoptotic factor also localized to mitochondria, results in rapid mitochondrial dysfunction characterized by initial hyperpolarization followed by eventual depolarization of mitochondria.

Rat-1 fibroblasts expressing the inducible myc-ER construct undergo myc-dependent apoptosis under low serum conditions. This model of apoptosis is also accompanied by increased ROS generation, as shown by the ROS-sensitive dye, dichlorofluorescein (DCFH). We characterized mitochondrial structure and function in Rat-1 cells according


to myc expression and serum conditions. 2 x 10<sup>5</sup> Rat-1 myc-ER cellswere plated in 10 cm dishes initially in phenol red-free DMEM with 10% FCS. After 1 day, cells were washed and switched to 0.1% FCS or recultured in 10% FCS. After an additional 2 days, myc induction was achieved by adding tamoxifen. Cells were tested for viability by trypan blue staining at successive time points. Mitochondrial staining with the fluorescent dye JC-1 was analyzed by flow cytometric measurement of FL-1 (green) and FL-2 (red) emissions. Specific staining of mitochondria by JC-1 includes a delta Ψm-independent component (green/monomers) and a delta Ψm-sensitive component (red/aggregates). Cells are harvested by trypsinization, incubated at 37° C with 1 μm JC-1 in culture media for 15 min, and analyzed using a Becton-Dickinson FACscan. At several time points, cell pellets were fixed in 1/2 strength Karnovsky's solution and processed for transmission electron microscopy.

Significant loss of viability only occured in tamoxifen-treated cells under low serum conditions. Cell death was first apparent at 48 hours after tamoxifen addition.

Morphology of dead cells was consistent with apoptotic death. Rat-1 cells transfected with vector controls (pBabe-neo) retained high viability for all conditions. JC-1 staining was altered in tamoxifen-treated cells, but only in combination with low serum. The initial pattern of JC-1 staining consisted of an increase in green fluorescence seen at 24 hours (Figure 1). Subsequently, green<sup>HI</sup> cells accumulated with low red staining. These

results suggested that mitochondria in myc-dependent apoptosis were initially triggered to proliferate and subsequently became depolarized.


Figure 1



Electron micrographs demonstrated structural alterations corresponding to the JC-1 patterns. Serum-deprived, myc-induced cells contained greater numbers of mitochondria than under basal conditions. Mitochondrial structure was also altered, with elongated mitochondrial shapes and numerous, non-aligned cristae. The matrix space appeared dense, in some instances obscuring the pattern of cristae. The ultrastructural appearance of mitochondria in myc-induced, serum-starved cells suggested increased biogenesis of mitochondria and a pattern of mitochondrial injury previously described as ultra condensation. Bcl-2-protected cells appeared to have milder structural alterations, with an increase in cristae density.

# Task 2 - Test of bcl-2 in murine mammary carcinogenesis models

A total of 72 transgenic MMTV-bcl-2 virgin female mice and 58 control littermates were treated with a total DMBA (dimethylbenzanthracene) dose of 6 mg and observed for the occurrence of mammary tumors. A small cooperative effect of bcl-2 on DMBA-induced mammary carcinogenesis was observed (Figure 2), however, an increase in tumor incidence/ week was only present at 7-8 weeks after the initiation of drug treatment.



As suppression of apoptosis was expected to be the mechanism of any interaction for bcl-2 with carcinogen exposure, we evaluated apoptosis within the mammary tumors for both genetic backgrounds. Mammary tumors were removed from mice at the time of

sacrifice, fixed in 10% neutral-buffered formalin and embedded in paraffin. Serial five-micron sections were processed by hematoxylin-eosin staining for tumor histology and TUNEL staining for apoptosis. Cells with TUNEL-positive nuclei were counted at high magnification from four random fields estimated to contain >80% tumor cells in a representative section from each tumor. Mammary tumors from control B6xC3H females had 14.2 +/- 4.8 apoptotic cells per high-power field (N = 7), while MMTV-bcl-2 transgenic-derived tumors had 20.5 +/- 12.7 apoptotic cells/hpf (N= 11). Transgenic mice were also noted to have non-uniform expression of the human Bcl-2 protein in mammary tumor sections, suggesting transgene down-regulation or silencing.

Our initial mating experience with MMTV-bcl-2 and myc mice resulted in few viable litters and we have had to set up additional mating pairs to obtain sufficient double transgenic females for analysis.

Task 3 - <u>Analysis of the expression of genes regulating apoptosis during physiologic</u> mammary epithelial cell death.

A cohort of virgin female FVB/N mice has been sacrificed with collection of mammary and vaginal tissues. Histologic staining of vaginal sections allows determination of the ovulatory cycle stage for paired mammary tissue blocks. Our initial examination of luteal phase mammary epithelium for Bcl-2, Bax, Bcl-x and Bak expression demonstrated

distinct patterns of expression for each protein. Bcl-2 is expressed in both ductal and lobular epithelium, although both regions are notably heterogenous. Bax is predominantly present in myoepithelial cells. Bcl-x has low expression with a fairly homogenous pattern. Finally, Bak is expressed principally in small terminal ductules.

Task 4 - Examination of hormonally treated and transgenic mice for apoptotic setpoints in mammary epithelium.

We have begun to collect mammary and vaginal tissue blocks from MMTV-myc and MMTV-bcl-2 females. Following the collection of these materials, we plan to initiate estrogen/progesterone treatment of cohorts using implanted osmotic pumps. We expect to be able to complete the analysis of these sections for apoptotic endpoints (TUNEL, Bcl-2 and related proteins) by the end of the year based on the assay throughput currently achievable in the lab.

### **Conclusions**

The recent evidence that metastatic breast tumor DNA has both increased hydroxyl radical-induced damage as well as greater diversity of modified bases (Malins and others, 1996) is consistent with a role of oxidative stress in tumor progression. As Bcl-2 appears to modulate oxidative stress, probably via its interaction with mitochondrial functions, the relationship between the expression of Bcl-2 and related proteins and tumor progression may provide important insights into this process and its mechanisms. If tumor initiation and progression are related to suppression of apoptosis, the primary function of bcl-2, apoptotic indices should decrease in relation to tumor yield. Although synergy between Bcl-2 and carcinogen exposure was demonstrable, it was less than anticipated, based on oncogene interactions in cell and animal cancer models. Alternatively, Bcl-2 expression and apoptosis rates may reflect a selective pressure for an "oxidative" cellular redox state to increase DNA damage in cancer cells. In this model, the accumulation of apoptotic cells might represent the "tip of the iceberg" as the overt manifestation of more widespread cellular derangements causing sublethal genomic damage.

Our observations that changes in mitochondrial mass and function are associated with activation of an apoptotic pathway may provide an in situ method to monitor "apoptotic setpoints" and determine whether cells with low apoptotic setpoints are cancer-prone.

#### References

Bhargava V, D L Kell, M van de Rijn, and R A Warnke. "Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity." <u>Am J Path</u> 145 (1994): 535-540.

Campos, L, J-P Roualult, O Sabido, P Oriel, N Roubi, C Vasselon, E Archimbaud, J-P Magaud, and D Guyotat. "High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy." <u>Blood</u> 18 (1993): 3091-3096.

Hockenbery, D. "Bcl-2, a novel regulator of apoptosis." Bioessays 17 (1995): 631-638.

Howard, M K, L C Burke, C Mailhos, A Pizzey, C S Gilbert, W D Lawson, M K L Collins, N S B Thomas, and D S Latchman. "Cell cycle arrest of proliferating neuronal cells by serum deprivation can result in either apoptosis or differentiation." J Neurochem 60 (1993): 1783-1791.

Joensuu H, L Pylkkanen, and S Toikkanen. "Bcl-2 protein expression and long-term survival in breast cancer." Am J Path 145 (1994): 1191-1198.

Lagasse, E, and I L Weissman. "bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages." J Exp Med 179 (1993): 1047-1052.

Leek, R D, L Kaklamanis, F Pezzella, K C Catter, and A L Harris. "bcl-2 in normal human breast carcinomas, association with oestrogen receptor-positive, epidermal growth factor-negative tumours and in situ cancer." <u>Br J Cancer</u> 69 (1994): 135-139.

Linette, G P, M J Grusby, S M Hedrick, T H Hansen, L H Glimcher, and S J Korsmeyer. "Bcl-2 is upregulated at the CD4+CD8+ stage during positive selection and promotes differentiation at several control points." <u>Immunity</u> 1 (1994): 197-205.

Malins, D C, N L Polissar, and S J Gunselman. "Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage." <u>Proc Natl Acad Sci USA 93 (1996)</u>: 2557-2563.

Miyazaki, T, Z-J Liu, A Kawahara, Y Minami, K Yamada, Y Tsujimoto, E L Barsoumian, R M Perlmutter, and T Taniguchi. "Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation." Cell 81 (1995): 223-231.

Pezzella, F, H Turley, I Kuzu, M F Tungekar, M S Dunnill, C B Pierce, A Harris, K C Gatter, and D Y Mason. "bcl-2 protein in non-small cell lung carcinoma." N Engl J Med 329 (1993): 690-694.

Pietenpol, J A, N Papadopoulos, S Markowitz, J K V Willson, K W Kinzler, and B Vogelstein. "Paradoxical inhibition of solid tumor cell growth by the bcl-2 cellular oncogene." Cancer Res 54 (1994): 3714-3717.

Rubin, L L, K L Philpott, and S F Brooks. "The cell cycle and cell death." <u>Current Biology</u> 3 (1993): 391-394.

Symonds H, L Krall, L Remington, M Saenz-Rubles, S Lowe, T Jacks and T Van Dyke. "p53-dependent apoptosis suppresses tumor cell growth and differentiation in vivo." Cell 78 (1994): 703-711.